Optimizing timing and cost-effective use of plasma biomarkers in Alzheimer’s disease
Abstract Background and objectives Early and cost-effective identification of amyloid positivity is crucial for Alzheimer’s disease (AD) diagnosis. While amyloid PET is the gold standard, plasma biomarkers such as phosphorylated tau 217 (pTau217) provide a potential alternative. This study evaluates...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-08-01
|
| Series: | Alzheimer’s Research & Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13195-025-01851-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|